Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448936 | 0.85 | MAPT (0.59) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL141303 | 0.85 | MAPT (0.59) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL1169369 | 0.85 | MAPT (0.60) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL30665998 | 0.85 | MAPT (0.60) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL25355624 | 0.82 | MEN1 (0.56) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL10845095 | 0.81 | MEN1 (0.54) | MAPTRAB9AMEN1KMT2ANPC1 | |
| Formaldehyde SCHEMBL27922643 | 0.81 | MAPT (0.56) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL31474894 | 0.80 | MAPT (0.56) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL14849221 | 0.80 | MAPT (0.56) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL20774271 | 0.80 | MAPT (0.56) | MAPTRAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327140-A1 | CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL | Gen-Probe Incorporated (US) | 2018-05-30 | — | — | EP | claimed |
| US-9938590-B2 | Capture probes immobilizable via L-nucleotide tail | GEN-PROBE INCORPORATED (US) | 2018-04-10 | — | — | US | claimed |
| EP-2616555-B1 | CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL | GEN PROBE INC (US) | 2017-11-08 | — | — | EP | claimed |
| US-20130260368-A1 | Capture Probes Immobilizable Via L-Nucleotide Tail | GEN-PROBE INCORPORATED (US) | 2013-10-03 | — | — | US | claimed |
| EP-2616555-A1 | CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL | Gen-Probe Incorporated (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037531-A1 | CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL | GEN-PROBE INCORPORATED (US) | 2012-03-22 | — | — | WO | claimed |
| US-11035012-B2 | Capture probes immobilizable via L-nucleotide tail | GEN-PROBE INCORPORATED (US) | 2021-06-15 | — | — | US | disclosed |
| US-20180251862-A1 | Capture Probes Immobilizable Via L-Nucleotide Tail | BANK OF AMERICA, N.A., AS COLLATERAL AGENT | 2018-09-06 | — | — | US | disclosed |
| EP-3327140-A1 | CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL | Gen-Probe Incorporated (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9938590-B2 | Capture probes immobilizable via L-nucleotide tail | GEN-PROBE INCORPORATED (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2616555-B1 | CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL | GEN PROBE INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20130260368-A1 | Capture Probes Immobilizable Via L-Nucleotide Tail | GEN-PROBE INCORPORATED (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2616555-A1 | CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL | Gen-Probe Incorporated (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037531-A1 | CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL | GEN-PROBE INCORPORATED (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | MAPT 4865/4885RAB9A 2575/4885MEN1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.